Go to Top

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer.

Conferences

Conference Participation

2016

San Antonio Breast Cancer Symposium (SABCS)
December 6-10, 2016| San Antonio, TX
Title: Phase 1/2 study of oral seviteronel (VT-464), a dual CYP17-lyase inhibitor and androgen receptor (AR) antagonist, in patients with advanced AR positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)
AuthorsGucalp A, Bardia A, Gabrail N, DaCosta N, Danso M, Elias AD, Ali H, Lemon SJ, Riley EC, Eisner JR, Fleming RA, Kurman MR, Moore WR, Traina TA.

PCF’s 23rd Annual Scientific Retreat
October 27-29,  2016| Carlsbad, CA
Edwina Baskin-Bey, CMO
William Moore, CEO

Canaccord Genuity Growth Conference
August 10-11, 2016 | Boston, MA
Innocrin Company Presentation
William Moore, CEO

American Society of Clinical Oncology (ASCO)
June 3-7, 2016 | Chicago, IL
Abstract #1088
Session: Breast Cancer – Triple Negative/Cytotoxics/Local Therapy, 6/5/2016 8:00-11:30
Title: Phase (Ph) 1 study of oral Seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC).
Authors: A Bardia, N DaCosta, N Gabrail, SJ Lemon, M Danso, H Ali, R Fleming, MR Kurman, JR Eisner, WR Moore, A Gucalp, TA Traina

 

Center for Entrepreneurial Development (CED) Life Sciences Conference 
March 1-2, 2016 | Raleigh, NC
Innocrin Company Presentation
Presentation can be viewed at:
Presentation at CED Conference
William Moore, CEO

American Society of Clinical Oncology, Genitourinary (ASCO GU)
January 7-10, 2016 | San Francisco, CA

Citation: J Clin Oncol 34, 2016 (suppl 2S; abstr 198)
Title: Cardiovascular Safety Profile of VT-464 in Patients (Pts) with Castrate-Resistant Prostate Cancer (CRPC).  
AuthorsM Kurman, P Sager, M Rudoltz, J Eisner, D Goodman, E Heyman, D Salvail, C Bell, W Moore

 

Citation: J Clin Oncol 34, 2016 (suppl 2S; abstr 273)
Title: Efficacy of the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist, VT-464, in patients with CRPC.  
Authors: L Nordquist, N Shore, J de Bono, S Gupta, W Berry, S Gillessen, G Liu, N Vogelzang, E Efstathiou, M Fleming, D George, J Arujo, J-S Zhang, M Kurman, J Eisner, W Moore

 

Citation: J Clin Oncol 34, 2016 (suppl 2S; abstr 343)
Title: Once-nightly (QD) dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist VT-464 in patients with CRPC
Authors: N Shore, L Nordquist, S Gupta, M Fleming, W Berry, JS Zhang, M Kurman, J Eisner, W Moore

2015

San Antonio Breast Cancer Symposium (SABCS)
December 8-12, 2015 | San Antonio, TX

Citation: Cancer Res 2016;76(4 Suppl):Abstract nr OT2-01-03.
Title: A phase 1/2 study of once-daily oral VT-464 in patients with advanced androgen receptor (AR) positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC).
Authors: A Gucalp A, C Hudis, L Norton, S Pat, MR Kurman, JR Eisner, WR Moore, TA Traina

 

Citation: Cancer Res 2016;76(4 Suppl):Abstract nr P3-14-04.
Title: Effects of the dual selective CYP17 lyase inhibitor and androgen receptor (AR) Antagonist VT-464, on AR+ and ER+ tumor models in vitro and in vivo.
Authors: SJ Ellison, JD Norris, S Wardell, JR Eisner, WJ Hoekstra, DB Stagg, HM Alley, WR Moore, DP McDonnell

 

Southeast BIO Investor and Partnering Forum
Nov 11-13, 2015 | Charleston, SC
Innocrin Company Presentation
William Moore, CEO

22nd Annual Prostate Cancer Foundation (PCF) Annual Retreat
October 7-10 2015 | Washington, DC                                  
Title: A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of VT-464 in Patients with Castration-Resistant Prostate Cancer (CRPC) Progressing on Enzalutamide (ENZ) or Abiraterone Acetate (AA).
Authors: H Scher, B Montgomery, M-E Taplin, EA Mostaghel, W Abida, M Kurman, JR Eisner, WR Moore  

American Society of Clinical Oncology, Genitourinary (ASCO GU)
February 26-28, 2015 | Orlando, FL
Citation: J Clin Oncol 33, 2015 (suppl 7; abstr 187)
Title: The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC.
AuthorsJS De Bono, CJ Pezaro, S Gillessen, ND Shore, LT Nordquist, E Efstathiou, JC Araujo, WR Berry, G Liu, NJ Vogelzang, AG Omlin, RJ Schotzinger, JR Eisner, WR Moore

 

Citation: J Clin Oncol 33, 2015 (suppl 7; abstr 263)
Title: Direct effects of the selective CYP17 lyase (L) inhibitor, VT-464, on the androgen receptor (AR) and its oral activity in an F876L tumor mouse xenograft model.
AuthorsWR Moore, JD Norris, S Wardell, JR Eisner, WJ Hoekstra, RJ Schotzinger, DP McDonnell